BRIEF—Entyvio analyses show improvements in ulcerative colitis or Crohn's disease

Takeda Pharmaceutical has announced the presentation of data suggesting early symptomatic improvement in specific symptoms with Entyvio (vedolizumab) in patients with moderately to severely active ulcerative colitis (UC) or Crohn’s disease (CD), particularly in biologic-naïve patients for whom other therapies have not worked well enough.

In two post-hoc analyses of GEMINI data in patients with UC and CD, symptomatic improvements were evaluated with Entyvio at weeks two, four and six, specifically in Mayo Clinic sub-scores of rectal bleeding and stool frequency in UC, and patient-reported outcome subscores in CD such as abdominal pain and number of liquid or very soft stools.

In patients who reported improvements, the greatest differences from placebo were observed in biologic-naïve patients versus the overall treatment group, some as early as week two.